Replies to post #48185 on Anavex Life Sciences Corp (AVXL)

[JB3729]

On 1/12/15, Anavex announced that the first patient had been dosed -

http://www.anavex.com/?news=anavex-doses-first-alzheimers-patient-in-phase-2a-trial-of-anavex-2-73-and-anavex-plus

57 weeks later, this patient should complete the trial.

I have read that patients in other trials would be allowed to continue dosing until the trial ended. I don't know if that is the case in this trial.

I think AVXL will continue to release data the way they did on 11/9 when they gave us all patients at 5 weeks and 14 patients after the additional 12 weeks. Next, I'm guessing we'll see all patients at 12 weeks of PART B and ~14 patients at 24 or 26 weeks.